首页> 外文OA文献 >Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

【2h】

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

机译：用于随机，双盲，安慰剂控制，并行组，调查员启动的第2A的研究的理由和设计，以研究Elobixibat与非酒精性脂肪肝病的胆甾胺组合的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Takaomi Kessoku; Takashi Kobayashi; Anna Ozaki; Michihiro Iwaki; Yasushi Honda; Yuji Ogawa; Kento Imajo; Yusuke Saigusa; Koji Yamamoto; Takeharu Yamanaka; Haruki Usuda; Koichiro Wada; Masato Yoneda; Satoru Saito; Atsushi Nakajima;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design [J] . Kessoku Takaomi, Imajo Kento, Kobayashi Takashi, Contemporary clinical trials . 2018,第期

机译：润滑酮治疗成人便秘患者非酒精性脂肪肝病的疗效，安全性和耐受性：润滑，双盲，随机，安慰剂控制研究设计
2. Rationale and design of the MODIFY study: A phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease [J] . Molecular genetics and metabolism . 2020,第2期

机译：修饰研究的理由和设计：第3阶段多中心，双盲，随机，安慰剂控制，并行群体研究，以确定Lucerastat口服单药治疗成人对象的疗效和安全性
3. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial [J] . Idorn Thomas, Knop Filip K., Jorgensen Morten B., Diabetes care . 2016,第2期

机译：利拉鲁肽在2型糖尿病和终末期肾脏疾病患者中的安全性和有效性：研究者发起，安慰剂对照，双盲，平行分组，随机试验
4. Rationale and design of a randomised double-blind placebo-controlled parallel-group investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease [O] . Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, 2020

机译：用于随机双盲安慰剂控制并行组调查员启动的第2A的研究的理由和设计以研究Elobixibat与非酒精性脂肪肝病的胆甾胺组合的疗效和安全性
5. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction [O] . C. Michael Gibson, John J.P. Kastelein, Adam T. Phillips, 2021

机译：Apoa-i事件的理由和设计减少缺血综合征II（AEGIS-II）：3阶段，多中心，双盲，随机，安慰剂控制，并行组研究，以研究CSL112在受试者中的疗效和安全性急性心肌梗塞

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

著录项

相似文献

相关主题

期刊订阅